-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Trade Alert: The Chairman Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737), Zhi Tian Lai, Has Just Spent CN¥3.4m Buying A Few More Shares
Trade Alert: The Chairman Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737), Zhi Tian Lai, Has Just Spent CN¥3.4m Buying A Few More Shares
Potential Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders may wish to note that the Chairman, Zhi Tian Lai, recently bought HK$3.4m worth of stock, paying HK$0.95 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
Check out our latest analysis for Zhongzhi Pharmaceutical Holdings
Zhongzhi Pharmaceutical Holdings Insider Transactions Over The Last Year
Notably, that recent purchase by Zhi Tian Lai is the biggest insider purchase of Zhongzhi Pharmaceutical Holdings shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of HK$1.02. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Zhongzhi Pharmaceutical Holdings share holders is that insiders were buying at near the current price.
In the last twelve months Zhongzhi Pharmaceutical Holdings insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
SEHK:3737 Insider Trading Volume May 2nd 2022There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
Insider Ownership of Zhongzhi Pharmaceutical Holdings
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Zhongzhi Pharmaceutical Holdings insiders own about HK$538m worth of shares (which is 61% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
So What Do The Zhongzhi Pharmaceutical Holdings Insider Transactions Indicate?
It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Zhongzhi Pharmaceutical Holdings. Looks promising! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 4 warning signs for Zhongzhi Pharmaceutical Holdings and we suggest you have a look.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Potential Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) shareholders may wish to note that the Chairman, Zhi Tian Lai, recently bought HK$3.4m worth of stock, paying HK$0.95 for each share. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.
电势中智医药控股有限公司(HKG:3737)股东不妨留意,主席智天来最近买入价值340万港元的股票,每股作价0.95港元。然而,它只增加了一小部分股权,从绝对值来看,这也不是一笔大笔收购。
Check out our latest analysis for Zhongzhi Pharmaceutical Holdings
查看我们对中智医药控股的最新分析
Zhongzhi Pharmaceutical Holdings Insider Transactions Over The Last Year
中智医药控股去年的内幕交易
Notably, that recent purchase by Zhi Tian Lai is the biggest insider purchase of Zhongzhi Pharmaceutical Holdings shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of HK$1.02. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. The good news for Zhongzhi Pharmaceutical Holdings share holders is that insiders were buying at near the current price.
值得注意的是,智天来最近的收购是我们去年看到的最大规模的中智医药控股股票内幕收购。这意味着,一位内部人士乐于以目前1.02港元的价格买入股票。尽管他们的观点可能在收购后发生了变化,但这至少表明他们对公司的未来充满信心。我们总是喜欢看到内幕收购,但值得注意的是,这些收购是在远低于今天股价的情况下进行的,因为相对于价值的折扣可能随着股价的上涨而收窄。对于中智医药控股的股东来说,好消息是,内部人士以接近当前价格的价格买入。
In the last twelve months Zhongzhi Pharmaceutical Holdings insiders were buying shares, but not selling. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
在过去的12个月里,中智医药控股的内部人士在买入股票,但没有卖出。下面的图表显示了过去一年的内幕交易(按公司和个人)。如果你点击图表,你可以看到所有的个人交易,包括股票价格、个人和日期!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.
还有很多其他公司让内部人士买进股票。你很可能会这么做不想怀念这一切吗?免费内部人士正在收购的成长型公司名单。
Insider Ownership of Zhongzhi Pharmaceutical Holdings
中智医药控股的内部人所有权
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Zhongzhi Pharmaceutical Holdings insiders own about HK$538m worth of shares (which is 61% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
对于一个普通股股东来说,公司内部人士持有多少股份值得一查。我们通常希望看到相当高水平的内部人士持股。中智医药控股的内部人士持有价值约5.38亿港元的股份(占公司股份的61%)。这种由内部人士持有的重大所有权通常确实增加了公司以所有股东的利益运营的机会。
So What Do The Zhongzhi Pharmaceutical Holdings Insider Transactions Indicate?
那么,中智医药控股的内幕交易意味着什么呢?
It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Zhongzhi Pharmaceutical Holdings. Looks promising! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. You'd be interested to know, that we found 4 warning signs for Zhongzhi Pharmaceutical Holdings and we suggest you have a look.
很高兴看到最近的采购。我们还从更长期的内幕交易图景中获得信心。除了较高的内部人持股比例,这一分析表明,内部人士相当看好中智医药控股。看起来很有希望!虽然我们喜欢知道内部人士的所有权和交易情况,但在做出任何投资决定之前,我们也要确保考虑到一只股票面临的风险。你会有兴趣知道,我们发现了中智医药控股的4个警告标志,我们建议你看看。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费列出了一些有趣的公司,这些公司拥有高股本回报率和低债务。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
这篇由《华尔街日报》撰写的文章本质上是笼统的。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。简单地说,华尔街在提到的任何股票中都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧